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G protein-coupled receptors (GPCRs) have been classically described as monomeric entities that function
by binding in a 1:1 stoichiometric ratio to both ligand and downstream signalling proteins. However, in
recent years, a growing number of studies has supported the hypothesis that these receptors can interact
to form dimers and higher order oligomers although the molecular basis for these interactions, the
overall quaternary arrangements and the functional importance of GPCR oligomerization remain topics
of intense speculation.
Muscarinic acetylcholine receptors belong to class A of the GPCR family. Each muscarinic receptor
subtype has its own particular distribution throughout the central and peripheral nervous systems. In the
central nervous system, muscarinic receptors regulate several sensory, cognitive, and motor functions
while, in the peripheral nervous system, they are involved in the regulation of heart rate, stimulation of
glandular secretion and smooth muscle contraction. Muscarinic acetylcholine receptors have long been
used as a model for the study of GPCR structure and function and to address aspects of GPCR dimer-
ization using a broad range of approaches. In this review, the prevailing knowledge regarding the qua-
ternary arrangement for the various muscarinic acetylcholine receptors has been summarized by
discussing work ranging from initial results obtained using more traditional biochemical approaches to
those generated with more modern biophysical techniques.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Contents
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Dimerization of G protein-coupled receptors (GPCRs), that is the
structural arrangement of these receptors in pairs (dimers) at the
cellular plasma membrane or within other intracellular membrane
structures, and its functional signiﬁcance remain controversial
subjects that have been at the centre of debate for decades. Broadly
speaking, at least for class A, rhodopsin-like, receptors the GPCR
monomer represents the minimal receptor functional unit (Kuzak
et al., 2009; Whorton et al., 2007). However, it is now accepted
that receptor dimers, whether homo- or hetero-dimers, not onlyunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
oligomerization, Neuropharmacology (2017), https://doi.org/10.1016/
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play important roles in receptor ontology and function (Farran,
2017; Franco et al., 2016; Gahbauer and B€ockmann, 2016;
Margeta-Mitrovic et al., 2000, Milligan, 2004, 2009; 2013; Smith
and Milligan, 2010) as they can display distinct and novel phar-
macological features compared to the corresponding monomers.
GPCRs can form not only dimers but also higher-order oligomers
where more than two protomers interact as a functional or struc-
tural complex, further increasing the complexity of the subject
(Marsango et al., 2015a; Navarro et al., 2016; Patowary et al., 2013;
Liste et al., 2015). However, one of the caveats of many of the ap-
proaches applied to study receptor ‘dimerization’ is an inability of
these to resolve and specify whether a detected complex is strictly
dimeric or potentially oligomeric. As such the terms ‘dimeric’ and
‘oligomeric’ are often used imprecisely and without intention to
specify this feature.
The visual receptor rhodopsin is possibly the clearest example of
a class A GPCR demonstrated to be present as a ‘dimer’ in its native
setting. Employing atomic force microscopy rhodopsin appears as
densely packed rows of pairs of protomers in native mouse disc
membranes (Liang et al., 2003; Fotiadis et al., 2006). Although
potential caveats in interpretation of these images have been
highlighted (Chabre et al., 2003; Suda et al., 2004), such studies
provide strong support for the idea that, when in close proximity,
the structural organization of the basic 7-transmembrane domain
architecture of members of the GPCR family can allow receptor
protomers to pack together to allow close association and potential
direct physical interactions. This has opened new avenues for
studies of receptor function and organization related not only to the
molecular structure of potential receptor dimers but also in relation
to their interaction with signal transducer proteins including G
proteins and arrestins (Ferre et al., 2014; Navarro et al., 2016; Szalai
et al., 2012). In certain cases, principally for members of the class C,
or glutamate-like, family of GPCRs, homo- or hetero-dimeric or-
ganization is a pre-requisite for function (Ferre et al., 2014; Kniazeff
et al., 2011; Lane and Canals, 2012; Vafabakhsh et al., 2015). For
example, metabotropic GABAB receptors display an absolute
requirement for the co-expression of two distinct 7-
transmembrane domain polypeptides (GABAB receptor 1 (GABAB
R1) and GABAB receptor 2 (GABAB R2)), derived from distinct genes,
to form hetero-dimers to allow the complex to reach the cell sur-
face and act as a functional unit (Ng et al., 1999; Kuner et al., 1999).
These GPCRs have also been found to showmarked disparity in the
ligand binding properties of the dimer, depending on the speciﬁc
two subunits present within the complex. The function of the
agonist gabapentin at hetero-dimers formed by distinct splice
variants of the GABABR1 (GABABR1a/1b) with the GABABR2 is
reportedly very different; in that at GABABR1a/GABABR2 hetero-
dimers it acted as an agonist whilst it lacked activity at the
GABABR1b/GABABR2 hetero-dimer (Ng et al., 2001). Similar
changes in ligand binding and functional properties of hetero-di-
mers compared to the corresponding GPCR homo-dimers or
monomers have also been reported for some class A GPCRs, for
example the k and d opioid receptors (Jordan and Devi, 1999).
2. Muscarinic acetylcholine receptors
The muscarinic acetylcholine receptor family consists of ﬁve
members (M1R-M5R) and has long been established as a paradigm
for the study of GPCR structure and function, as well as for the
development of non-orthosteric receptor ligands. However, the
high degree of similarity of the binding pocket for acetylcholine
across the family members has hindered the identiﬁcation of se-
lective orthosteric ligands. As of 2016 multiple crystal structures of
four of the receptor subtypes bound by various ligands have beenPlease cite this article in press as: Marsango, S., et al., Muscarinic receptor
j.neuropharm.2017.11.023obtained (Haga et al., 2012; Kruse et al., 2012; Thal et al., 2016),
leaving only the structure of M5R to be determined. Consequently,
details of the atomic level structures have begun to be used in
structure-based drug design for the identiﬁcation of subtype se-
lective ligands, whilst also promoting understanding of themode of
binding of various classes of allosteric modulators (Kruse et al.,
2014; Miao et al., 2016). Continuing efforts to use such structure-
based drug design is resulting in signiﬁcant advances, as dis-
cussed elsewhere in this volume.
Although none of the currently available crystal structures of
muscarinic receptor subtypes shows a dimeric arrangement of the
receptor, information inferred from the arrangements of the a-
helices of the transmembrane domains and potential interaction
interfaces identiﬁed from both modelling studies and comparisons
with atomic level structures of other class A receptors where
dimeric contacts have been observed (Geng et al., 2016; Huang
et al., 2013; Manglik et al., 2012), have been used to design
rational hypotheses for the study of the molecular basis of
muscarinic receptor dimerization.
Interestingly, as will be discussed later, studies on both
muscarinic M1 and M2 receptors have suggested that these can
present in multiple co-existing and interchanging states, in both
transfected model cell systems and in native tissues, with some
reports indicating that contacts are ﬂeeting and may be generated
by different regions of the receptor structure (Hern et al., 2010;
Nenasheva et al., 2013). By contrast other reports suggest that
these receptors exist predominantly if not exclusively as dimers
(Herrick-Davis et al., 2013) or even as tetramers (Pisterzi et al.,
2010; Redka et al., 2013, 2014; Shivnaraine et al., 2016a). Deﬁning
this more clearly and assessing why different approaches appear to
result in quite distinct conclusions is a key issue for further research
on muscarinic receptor (and other GPCRs) dimerization. Finally, a
number of studies, both theoretical and experimental, suggest that
key interactions between receptor protomers are more likely to be
mediated via lipid-based contacts rather than, or in addition to,
direct protein-protein interactions (Gupta et al., 2017). Given the
long standing interest in muscarinic receptor function and phar-
macology, it is hardly surprising that this family of receptors has
been used as a model to address aspects of receptor dimerization
using a wide range of approaches. In addition to the potential for
muscarinic receptor interactions to be intrinsically dynamic, there
are recent new insights into the extent to which such interactions
can also be regulated by receptor expression levels and by both
certain receptor ligands and other receptor-interacting molecules
and toxins (Hirschberg and Schimerlik, 1994; Ilien et al., 2009;
Alvarez-Curto et al., 2010a; Hern et al., 2010; Hu et al., 2013;
Nenasheva et al., 2013; Patowary et al., 2013; Liste et al., 2015;
Aslanoglou et al., 2015; Pediani et al., 2016).
This review will examine earlier work and overlay this with
results being derived from more recently adopted approaches (see
Table 1).
The ﬁrst observations suggesting that muscarinic acetylcholine
receptors might be arranged in dimers and/or higher-order oligo-
mers were based on results from radioligand binding studies
(Potter et al., 1991; Hirschberg and Schimerlik, 1994; Wreggett and
Wells, 1995). In the early 1990s, for example, the complex proﬁle of
the competition curves between [3H]NMS and various agonists to
the M2R were interpreted as reﬂecting the presence of two agonist
binding sites (guanine nucleotide-sensitive high afﬁnity (H) and
low afﬁnity (L) sites) located on dimeric M2R molecules in rabbit
heart and rat brain stem (Potter et al., 1991). Likewise, computer
simulation of the kinetics of binding of the agonist [3H]oxo-
tremorine-M at the porcine M2R were consistent with the receptor
existing as a mixture of monomers and potentially asymmetrical
dimers (with one ligand-bound protomer while the secondoligomerization, Neuropharmacology (2017), https://doi.org/10.1016/
Table 1
Summary of approaches used to detect dimers and/or higher-order oligomers of muscarinic receptor subtypes.
Technique Receptor subtype/model system Reference
Binding assays M2R; heart tissue Mattera et al., 1985
M2R; heart tissue Galper et al., 1987
M1R; brain Potter et al., 1991
M2R; M3R heterologous system Maggio et al., 1999
M2R; phospholipid vesicles Redka et al., 2013
M2R; phospholipid vesicles Redka et al., 2014
Photo-afﬁnity labelling M1R; brain Avissar et al., 1983
Western blot/Co-Immunoprecipitation M3R; heterologous system Wreggett and Wells, 1995
M3R; heterologous system Zeng and Wess, 1999
M2R; heterologous system Park and Wells, 2004
M3R; heterologous system Hu et al., 2012
M3R; heterologous system Hu et al., 2013
M3R; heterologous system Liste et al., 2015
M3R; heterologous system Pediani et al., 2016
BRET M1R, M2R, M3R; heterologous system Goin and Nathanson, 2006
M1R; heterologous system Marquer et al., 2010
M3R; heterologous system McMillin et al., 2011
FRET/htrFRET M3R; heterologous system Alvarez-Curto et al., 2010a
M2R; heterologous system Pisterzi et al., 2010
M3R; heterologous system Patowary et al., 2013
M3R, M2R; heterologous system Aslanoglou et al., 2015
M3R; heterologous system Liste et al., 2015
TIRF M1R; heterologous system Hern et al., 2010
M2R; heart tissue and heterologous system Nenasheva et al., 2013
SpIDA M1R, M3R; heterologous system Pediani et al., 2016
FCS M1R, M2R; heterologous system Herrick-Davis et al., 2013
S. Marsango et al. / Neuropharmacology xxx (2017) 1e10 3remained unbound) in cultured cells and in porcine atrium
(Hirschberg and Schimerlik, 1994). This work also highlighted the
impact that levels of receptor expression may have on the equi-
librium between monomers and dimers and suggested a degree of
cooperativity between protomers in ligand binding (Hirschberg
and Schimerlik, 1994). This cooperativity has been further re-
ﬂected in additional studies on M2R where binding data were
interpreted in terms of cooperative interactions within receptors
organized in higher-order oligomers such as homo-trimers or
homo-tetramers (Wreggett and Wells, 1995). This piece of work
was also one of the ﬁrst to show biochemical support for the
multimeric nature of theM2R, as shown in SDS-polyacrylamide gels
of puriﬁed receptors from porcine atrial tissue (Wreggett andWells,
1995). Wells and collaborators have made extensive use of ligand
binding studies to gain further insights into the pharmacological
proﬁle of M2R (Redka et al., 2013, 2014). In competition binding
studies, using [3H]NMS and seven diverse agonists, these authors
observed a dispersion of afﬁnity, indicative of two or more classes
of sites (Redka et al., 2013). This has traditionally been explained as
the effect of the G protein on an otherwise homogeneous popula-
tion of sites in studies in which the aggregation state of the M2R
was not taken into consideration (Birdsall et al., 1978; Ehlert, 1985;
Berrie et al., 1979). With this purpose, these authors compared two
forms of the puriﬁedM2R devoid of G protein and reconstituted as a
monomer in micellar dispersion or as a tetramer in phospholipidic
vesicles (Redka et al., 2013). They concluded that the heterogeneity
revealed by the seven agonists at theM2R is intrinsic to the receptor
tetrameric state, is independent of coupling to G protein and it is, at
least in part, a consequence of the cooperativity between linked
orthosteric sites (Redka et al., 2013). In subsequent work designed
to identify the biologically relevant form of M2R, studies compared
the ligand binding properties and the effect on the binding proﬁle
of the poorly-hydrolysed analogue of GTP, guanosine 5’-[b,g-imido]
triphosphate (GMP-PNP), on reconstituted M2R monomers and
tetramers, with muscarinic receptors present natively in sarco-
lemmal membranes (Redka et al., 2014). They concluded that
tetrameric but not monomeric forms of the M2R resemble musca-
rinic receptors in such myocardial membranes and suggested thatPlease cite this article in press as: Marsango, S., et al., Muscarinic receptor
j.neuropharm.2017.11.023the M2R may signal as an oligomer (Redka et al., 2014).
Returning to the early 1990s, in an attempt to study the folding
and assembly of GPCRs, Maggio and collaborators (Maggio et al.,
1993) generated two hybrid M3R/a2C-adrenergic receptors in
which the ﬁrst ﬁve transmembrane domains (TM) I-V of one re-
ceptor were fused to TMVI and VII of the second and vice-versa
(Maggio et al., 1993). Expression of the individual hybrids was
unable to result in stimulation of phosphoinositide (PI) hydrolysis
in an agonist-dependent fashion or to allow detection of either
adrenergic or muscarinic radioligand binding activity (Maggio
et al., 1993). In contrast, co-expression of the two hybrid re-
ceptors resulted in the appearance of bothmuscarinic [3H]NMS and
adrenergic [3H]rauwolscine binding sites and, following incubation
of cells co-transfectedwith the two hybrid receptors themuscarinic
agonist carbachol generated an increase in PI hydrolysis (Maggio
et al., 1993). Such ‘rescue’ of receptor activity was interpreted to
reﬂect direct interactions between the two hybrid receptors
forming a dimeric complex that allowed the reconstitution of
functional receptor units (Maggio et al., 1993). Interestingly, co-
expression of short hybrid M3R/a2C-adrenergic receptors in which
196 amino acids were deleted from the internal loop 3 (IL3) pre-
vented the reconstitution of functional receptor units, suggesting a
role of the residues located in this internal loop in regulating M3R-
M3R interactions (Maggio et al., 1996).
Although these studies were consistent with the idea of at least
a proportion of muscarinic receptors being present as dimers and/
or oligomers, they did not provide any intrinsic evidence of a direct
physical interaction between protomers. This kind of evidence was
obtained sometime later when membrane preparations from rat
M3R (rM3R) expressing cells were analysed by Western blotting
under non-reducing conditions (Zeng and Wess, 1999). Such anal-
ysis showed several immunoreactive species corresponding in size
to putative rM3R monomers, dimers and oligomers. Although dif-
ferential mobility in such gels is challenging to interpret and can
reﬂect protein aggregation stemming from the preparation condi-
tions, subsequent co-immunoprecipitation studies provided
further support for the formation of non-covalently associated
rM3R dimers and oligomers expressed within transfected COS-oligomerization, Neuropharmacology (2017), https://doi.org/10.1016/
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over, site-directed mutagenesis studies have demonstrated the
importance of disulphide-bond formation between conserved
cysteine residues located in the extracellular loops (ELs) 2 and 3 of
the rM3R for protomer-protomer interaction (Zeng and Wess,
1999). Wess and collaborators have made extensive use of West-
ern blot analysis in combination with cysteine substitutions and a
disulﬁde cross-linking strategy to gain insights into mechanisms of
muscarinic receptor dimerization (Hu et al., 2012, 2013). Recently,
they proposed a model in which rM3R-rM3R protomers interact to
form at least three structurally distinct dimeric species in which
protomer-protomer interactions occur as part of the formation of
three distinct interfaces. The ﬁrst proposed dimeric interface, the
TMV-TMV interface (Hu et al., 2012), involves residues at the
cytosolic end of TMV, the second, the TMIV-TMV-IL2 interface, in-
volves residues in IL2, whilst the third involves residues from the
carboxy-terminal Helix VIII and has been designated the TMI-TMII-
Helix VIII interface (Hu et al., 2013). Treatment of rM3R-expressing
COS-7 cell membranes with the muscarinic agonist carbachol was
indicated to bewithout effect on the cross-linking pattern observed
using mutants in each of TMV, IL3 or IL2, supporting a hypothesis
that TMV-TMV rM3R and TMIV-TMV-IL2 rM3R dimers form in a
constitutive fashion and that these arrangements remain un-
changed upon rM3R activation. In contrast, agonist-treatment of
COS-7 cell membranes expressing rM3R-mutants within Helix VIII
resulted in an increase in the efﬁciency of receptor cross-link for-
mation (Hu et al., 2012, 2013).
Although approaches such as immunoblotting, cross-linking
and co-immunoprecipitation have been employed to study the
basis of GPCR dimerization/oligomerization, they have limitations
for the study of interactions involving integral membrane proteins
due to the use of non-physiological buffers and detergents that may
cause either non-native aggregation or disruption of native bio-
logical interactions. Those limitations have been addressed with
the development of biophysical methods based on resonance en-
ergy transfer (RET) between two molecules, known as the “donor”
and “acceptor,” positioned within a restricted distance (in the re-
gion of 2e8 nm) and deﬁned orientation (Alvarez-Curto et al.,
2010b; Ayoub and Pﬂeger, 2010; Ayoub, 2016). These include both
bioluminescence resonance energy transfer (BRET) and variants of
ﬂuorescence resonance energy transfer (FRET), and both have been
widely applied to the study of protein-protein interactions and the
dimerization of muscarinic receptors and other GPCRs in particular
(Goin and Nathanson, 2006; McMillin et al., 2011; Alvarez-Curto
et al., 2010a; Ciruela et al., 2010; Marsango et al., 2015a; Sposini
et al., 2015).
The most signiﬁcant difference between these approaches is
that BRET measures energy transfer between a bioluminescent
donor (most usually variants of the luciferase from Renilla reni-
formis) and a ﬂuorescent acceptor (eYFP, GFP or other) while FRET
takes place between two ﬂuorescent proteins with overlapping
emission and excitation spectra (of the donor and acceptor,
respectively) after the excitation of the donor molecule by an
external light source (Ciruela et al., 2010). In both FRET and BRET
studies, it is important to experimentally determine that the energy
transfer (E(RET)) between donor- and acceptor-tagged species ex-
ceeds the E(RET) between the co-expressed and unlinked donor and
acceptor molecules, in order to be able to distinguish between
speciﬁc oligomerization and random collisions. Moreover, the
(E(RET)) between donor- and acceptor-tagged species should be
compared to that from donor- and acceptor-linked to known non-
interacting proteins.
An example of the use of RET techniques, in combination with
molecular studies and site-directed mutagenesis was also provided
by Wess and collaborators in a study in which the mechanism ofPlease cite this article in press as: Marsango, S., et al., Muscarinic receptor
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protomer-protomer interfaces of dimerization mapped (McMillin
et al., 2011). Mutants in which selected outward, lipid-facing resi-
dues within each of the TMs were simultaneously replaced by al-
anines were produced. By performing BRET assays using such
mutants the authors were able to identify residues in TMs I-V and
VII that impaired the ability of these variants to form dimers. The
results of this study were interpreted bymeans of a model inwhich
hM3R exists as multiple, energetically favourable, homo-dimers
characterized by different geometries and in which protomer-
protomer interactions could occur through each of TMV-TMV,
TMVI-TMVII, TMIV-TMV and TMI-TMII (McMillin et al., 2011, Fig. 1).
In broad agreement, Patowary et al., (2013) showed that at the
cell surface of a HEK293-derived cell line the hM3R is able to form
not only homo-dimers, but also higher-order oligomers. Herein
spectrally-resolved two-photon microscopy (SR-TPM) allowed
mathematical ﬁtting of the data to indicate the hM3R as being
predominantly tetrameric, with the contributing hM3R protomers
being organized in a rhombus-shaped complex. This tetrameric
form was shown to be in equilibrium with dimeric species
(Patowary et al., 2013, Fig. 1). This model has subsequently been
supported by mutational studies in which outward facing residues
of TMI, TMIV, TMV, TMVI, TMVII as well as Helix VIII were replaced
with alanines and the ability of such mutants to form dimers
assessed using homogeneous time-resolved FRET (htrFRET, see
below for further details) (Liste et al., 2015). Themutagenic strategy
was based on both the earlier studies described above (McMillin
et al., 2011) and molecular modelling studies that took as a start-
ing point a high resolution, inactive state, structure of rM3R (Kruse
et al., 2012). Although many mutants impaired the competence to
the receptor to generate effective interacting complexes, in no case
were protomer-protomer interactions fully abolished (Liste et al.,
2015). This also suggested the potential of the hM3R to form
higher-order complexes. To deﬁne these complexes, both rhombic
(Patowary et al., 2013) and linear (Manglik et al., 2012; Huang et al.,
2013) tetramer models were considered, as these were the only
ones in which modelling allowed the simultaneous binding of two
heterotrimeric G-proteins in their nucleotide-free form, as in the
atomic level crystal structure of the b2-adrenoceptor complexed
with nucleotide-free Gas (Rasmussen et al., 2011). However, even
though both models could explain roles for TMI and Helix VIII as
well as TMV and TMVI, only the rhombic-shaped tetramer was
compatible with a role of TMVII in a dimer þ dimer interface
involving TMVI-TMVII and part of TMI (Liste et al., 2015). This
model generated a complex of two dimers (in which protomer-
protomer interactions occur through an interface involving resi-
dues from TMI-TMII and Helix VIII) that interact to form a
dimer þ dimer interface utilizing residues from TMVI-TMVII and
part of TMI. Moreover, molecules of cholesterol were speciﬁcally
introduced into the model in positions that had already been
observed in other published class A GPCR crystal structures (Liste
et al., 2015). In particular, two cholesterols interacting with the
extracellular side of TMVI (making a total of four molecules in the
tetrameric complex) were suggested to form a buffer between the
dimers and to mediate interactions of TMVI with TMVII, as well as
with residues from TMI (Fig. 1). Molecules of cholesterol in equiv-
alent locations have been described in both the quaternary ar-
rangements of the adenosine A2A (Jaakola et al., 2008) and m-opioid
receptors (Manglik et al., 2012). Furthermore, these cholesterols
superimposed well with those observed in the extracellular side of
the TMVII of the P2Y12 receptor (Zhang et al., 2014). Twomolecules
of cholesterol were also described at the TMI- Helix VIII dimer
interface positioned as observed in the crystal structure of the b2-
adrenoceptor (Cherezov et al., 2007) and serotonin 5-HT2B (Wacker
et al., 2013) receptors. The organization of the M2R has also beenoligomerization, Neuropharmacology (2017), https://doi.org/10.1016/
Fig. 1. Quaternary organization of the hM3R. (A) Representation of the four distinct low energy M3R dimeric structures as described by McMillin et al., (2011). The transmembrane
domains identiﬁed as being important for hM3R protomer-protomer interactions are shown in grey circles. (Bi) Schematic representation of the quaternary arrangements of M3R as
described by Patowary et al., (2013). M3R can form rhombic-shaped tetramers and dimers that are in equilibrium at the cell membrane. (Bii) Molecular model of the M3R tetramer
with a rhombic arrangement as a complex of two dimers represented as grey and blue surfaces. Predicted molecules of cholesterol are shown as yellow spheres (Figure adapted from
Liste et al., 2015). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
S. Marsango et al. / Neuropharmacology xxx (2017) 1e10 5investigated using FRET-based approaches (Pisterzi et al., 2010).
Herein, as measured using combinations of ﬂuorescence intensity-
based microscopy and ﬂuorescence lifetime measurements, and in
accord with the ligand binding studies discussed earlier, these
studies also concluded that the M2R is present as a tetramer at the
cell surface of transiently transfected CHO-S cells. Subsequently, a
combination of single-particle photobleaching, FRET, dual-color
ﬂuorescence correlation and molecular dynamics produced
similar conclusions thatM2R exists as a tetramer, but also suggested
that each of the protomers in this arrangement is coupled to a Gi-
family G protein. This conclusion produces a complex of hetero-
octamers in which the adjacent protomers interact via an oligo-
merization interface composed of residues within TMIV and V and
in which each of the protomers directly communicates with its
coupled G protein and indirectly with the G protein coupled to a
neighbouring protomer (Shivnaraine et al., 2016a). In a parallel
study, Shivnaraine et al., (2016b) concluded that only interactions
between constituent protomers of an M2R oligomer complex could
explain the observed allosteric effects of ligand binding that are
characteristic of M2R in myocardial preparations. To monitor such
allosteric interactions, the authors developed an M2R conformation
sensor at the allosteric site, based on FRET between inserted ‘FlAsH’
(Hoffmann et al., 2010) sequences and the mCherry ﬂuorescent
protein and performed pharmacological assays involving mutants
engineered to preclude intramolecular effects (Shivnaraine et al.,
2016b).
Aside from efforts to deﬁne dimeric interfaces taking a strictly
structural perspective, RET techniques have been widely used to
detect muscarinic receptor dimers in living cells. In early studies,
Goin and Nathanson (2006) used BRET to demonstrate that each of
M1R, M2R andM3R have the ability to form both homo- and hetero-Please cite this article in press as: Marsango, S., et al., Muscarinic receptor
j.neuropharm.2017.11.023dimers that varied slightly in their interaction afﬁnities and sug-
gested a propensity to form homo-dimers rather than higher-order
or hetero-meric complexes. Such BRET studies, however, did not
allow discrimination between receptors at the cell surface and the
total receptor population present within the cell. Detection of
dimerization of the M3R has, therefore, been studied in greater
detail using FRET-microscopy to allow selection of speciﬁc regions
of interest, for instance, within the plasma membrane (Alvarez-
Curto et al., 2010a; Patowary et al., 2013).
Homogeneous time-resolved FRET (htrFRET), which does not
require the use of a microscope, has also been developed and
extensively used in the study of GPCR oligomerization (Maurel
et al., 2008). Herein, speciﬁc self-labelling protein tags e.g. SNAP,
CLIP or HALO tags (Alvarez-Curto et al., 2010a; Hussain et al., 2013;
Kolberg et al., 2013; Aslanoglou et al., 2015; Marsango et al., 2015a,
2015b; Ward et al., 2010) have been fused to (usually) the N-ter-
minal domain of a GPCR. Covalent labelling with speciﬁc lanthanide
(terbium or europium) cryptates that act as energy donor, and a
compatible energy acceptor allow htrFRET. Use of non-cell per-
meant substrates to label the tags allows the exclusive detection of
those receptors present at the cell surface. Additionally, the long
lifetime of emission from the donor lanthanide means that the
signal can be recorded at times after which short-lived cellular
autoﬂuorescence has decayed (Maurel et al., 2008; Alvarez-Curto
et al., 2010a; Hussain et al., 2013; Kolberg et al., 2013; Aslanoglou
et al., 2015; Marsango et al., 2015a, 2015b; Liste et al., 2015; Ward
et al., 2010). As well as basal homo-dimerization ofM3R and hetero-
dimerization of M2R/M3R at the cell surface (Alvarez-Curto et al.,
2010a; Aslanoglou et al., 2015; Liste et al., 2015) potential regula-
tion of homo-dimer and hetero-dimers formation by ligands has
also been investigated using such approaches (Alvarez-Curto et al.,oligomerization, Neuropharmacology (2017), https://doi.org/10.1016/
S. Marsango et al. / Neuropharmacology xxx (2017) 1e1062010a; Aslanoglou et al., 2015; Liste et al., 2015). To explore this
Alvarez-Curto et al., (2011) used combinations of wild type hM3R
and a genetically engineered form of this receptor designated as a
‘RASSL’ (Receptor Activated Solely by Synthetic Ligand) mutant
(Conklin et al., 2008; Pei et al., 2008; Dong et al., 2010). The hM3-
RASSL receptor incorporates mutations in TMIII and TMV that
render it unable to bind effectively the endogenous ligand, acetyl-
choline, whilst in parallel it acquired afﬁnity for the synthetic
ligand clozapine-N-oxide (CNO), (Alvarez-Curto et al., 2011). Cells
expressing both forms of these receptors (hM3Rþ hM3-RASSL) that
were tagged with appropriate pairs of ﬂuorescent proteins or with
SNAP/CLIP tags were used to demonstrate the presence of homo-
dimers (Alvarez-Curto et al., 2010a). Here, it was found that treat-
ment with the agonist carbachol signiﬁcantly reduced the FRET
signal whilst treatment with the muscarinic antagonist atropine
was without effect, suggesting that, in the presence of the agonist,
the complexity of the quaternary structure of the hM3R was
reduced (Alvarez-Curto et al., 2010a). However, when measure-
ments were focussed exclusively at the cell surface treatment with
appropriate selective agonists (carbachol and acetylcholine for the
wild type receptor and CNO for the RASSL) the oligomeric structure
becamemore complex (Alvarez-Curto et al., 2010a). Once more, the
antagonist atropine was without effect (Alvarez-Curto et al., 2010a;
Alvarez-Curto et al., 2011). Whilst these results appear contradic-
tory, conventional “imaging” FRET using pairs of ﬂuorescent pro-
teins monitors receptor proximity throughout the cell whereas
htrFRET using the self-labelling protein tags only detected re-
ceptors at the cell surface. This may reﬂect genuine differences in
the effects of ligands upon quaternary structure depending upon
cellular location but requires further analysis. The use of htrFRET to
analyse muscarinic receptor organization has been further exploi-
ted to concurrently monitor homo-dimers of hM3-RASSL or hM2R
and hM3-RASSL-hM2R hetero-dimers in cell co-expressing hM2R
and hM3R (Aslanoglou et al., 2015). Here once more, atropine had
no effect on the extent of dimerization, whilst the selective (in this
context) hM2R agonist, carbachol, caused an increase in level of
hM2R homo-dimerization and a reduction in the level of hM2R-
hM3-RASSL hetero-dimerization.
Recently, to gain further insights into the dimerization of GPCRs
and potential effects of ligand binding Milligan and collaborators
(Ward et al., 2015, 2017; Pediani et al., 2016; Marsango et al., 2017)
have adopted a biophysical technique, Spatial Intensity Distribution
analysis (SpIDA), developed by Wiseman and co-workers (Godin
et al., 2011, 2015; Barbeau et al., 2013). This allows the detection
of protein-protein interactions with a spatial resolution of 220 nm;
a limitation which is overcome by oversampling the laser spot
confocal volume and quantifying the excitation illumination vol-
ume for membrane oligomerization measurements as a surface as
opposed to a 3-dimensional volume (Pediani et al., 2017) Brieﬂy,
SpIDA is based upon the analysis of regions of interest (RoIs)
selected within laser scanning confocal images of cells expressing
the protein of interest tagged with, for example, an appropriate
monomeric ﬂuorescent protein (Godin et al., 2011, 2015; Barbeau
et al., 2013; Ward et al., 2015, 2017; Pediani et al., 2016;
Marsango et al., 2017). Images are then analysed by constructing
ﬂuorescence intensity histograms for the pixels within the RoI and
then applying super Poissonian distribution curves. From these,
both the average quantal brightness (QB) within the RoI and also
the mean ﬂuorescent intensity of the ﬂuorescent particles can be
calculated (Godin et al., 2011, 2015; Barbeau et al., 2013;Ward et al.,
2015, 2017; Pediani et al., 2016; Ward et al., 2017; Marsango et al.,
2017).
The normalization of such values for the QB of the ﬂuorescent
label alone (expressed in a manner which ensures that it is
appropriately located in cells and is in a monomeric state) allowsPlease cite this article in press as: Marsango, S., et al., Muscarinic receptor
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of interest (expressed as monomeric equivalent unit, MEU) and its
density (expressed as particles per mm2) (Zakrys et al., 2014; Ward
et al., 2015; Pediani et al., 2016). Thus, if a suitably tagged GPCR has
a QB twice that of the label in a monomeric state, then it is likely to
be a dimer.
In various studies in which the protein of interest was labelled
with monomeric enhanced Green Fluorescent Protein (mEGFP) for
example, the QB of the ﬂuorescent label alone was determined by
performing SpIDA measurements on the basolateral membrane of
cells expressing a single mEGFP modiﬁed at the N-terminal region
by incorporation of a palmitoylation þ myristoylation consensus
sequence (PM-mEGFP), to target the expression of the mEGFP to
the plasma membrane or the equivalent forms of mEGFP linked to
the C-terminal region of the monomeric, single transmembrane
domain protein CD86 (Zakrys et al., 2014; Ward et al., 2015; Pediani
et al., 2016; Marsango et al., 2017). For example, the analysis of the
full data set obtained with the PM-mEGFP construct showed these
to be distributed in Gaussian fashion with an MEU value very close
to 1. This indicates that across the range of expression levels ach-
ieved, PM-mEGFP was routinely observed as being monomeric and
that even at higher levels of expression it was not erroneously
identiﬁed as being dimeric or oligomeric (Pediani et al., 2016;
Marsango et al., 2017).
The ﬁrst class A GPCR to which this methodology was applied
was the serotonin 5HT2C receptor and it was found that the receptor
existed as a complexmixture of oligomeric states frommonomer to
higher-order oligomers, with themost commonly found state being
a dimer (Ward et al., 2015). Interestingly, upon treatment with a
number of receptor sub-type speciﬁc, but chemically distinct an-
tagonists, this state was transformed into a predominantly mono-
meric one. Importantly for the potential pharmacological and,
indeed clinical, relevance of these observations, washout of the
drugs resulted in reformation of the original, complex oligomeric
state, indicating the reversibility of the ligand effect (Ward et al.,
2015).
SpIDA has also been applied recently to study the effects of li-
gands on the quaternary structure of the M1R (Pediani et al., 2016).
At the basolateral membrane of cells expressing an M1R fused to
mEGFP, a 75%:25% mixture of M1R monomers to M1R dimers or
higher-order oligomers was detected in the basal state (Pediani
et al., 2016). Upon treatment with the M1R selective antagonist
pirenzepine a large shift from the predominantly monomeric basal
state, to a much more complex one containing receptor dimers and
oligomers was observed (see Fig. 2). A similar result was also pro-
duced by treatment with the chemically closely related M1R se-
lective antagonist telenzepine (Pediani et al., 2016). However, this
was not a general effect produced by all muscarinic antagonists. For
example, neither atropine nor N-methylscopalamine (NMS), pro-
duced a change in M1R oligomeric structure (Pediani et al., 2016).
Furthermore, although markedly selective for M1R at higher con-
centrations both pirenzepine and telenzepine can bind the M3R.
However, despite both being used at concentrations appropriate to
their lower afﬁnity at this receptor, neither antagonist was able to
affect the organizational structure of the M3R (Pediani et al., 2016).
This highlights that ligand regulation may be a receptor selective
phenomenon and further studies to understand the molecular
differences between M1R and M3R that result in this divergence
should be illuminating. Notably, although not often quoted in re-
ports on muscarinic receptor organization, earlier work by Ilien
et al., (2009) had already noted that pirenzepine could promote
M1R dimerization. These studies indicated that rapid ligand binding
to a site on the periphery of the receptor acts as a trigger for a series
of conformational changes. These, in turn, were suggested to allow
the ligand to access more deeply buried regions of the receptor,oligomerization, Neuropharmacology (2017), https://doi.org/10.1016/
Fig. 2. Pirenzepine and telenzepine alter the quaternary structure of hM1R, whilst atropine and NMS do not. The quaternary state of the hM1R is shown in a graph in which the
QB, presented as monomeric equivalent units (MEU), is plotted against the receptor expression level, presented as receptor per mm2, in cells not treated (black circle) or treated (open
circle) with pirenzepine (A), telenzepine (B), atropine (C) or NMS (D). The percentage of RoIs characterized by the prevalence of hM1R in monomeric (QB less than or equal to 1.274
(I)) and dimeric (QB bigger than 1.274 (IIþ)) state, in not treated (black bars) or antagonist treated (open bars) cells, is also indicated in the insert.
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corollary to this is the studies of Hern et al., (2010) who used a
single molecule imaging technique, with a resolution of 20 nm,
known as total internal reﬂection ﬂuorescence microscopy (TIRFM)
to identify and track in real time individual M1R molecules bound
to (ﬂuorescent) Cy3B-telenzepine.The receptors were found to be
randomly distributed in the outer membrane of transfected CHO
cells and at any given time 30% were in the form of dimers, in broad
agreement with the work of Pediani et al., (2016).
Hern et al., (2010) considered “dimers” to be those tracks whose
intensity was double that of the single ﬂuorophore-ligand non-
speciﬁcally bound to the glass slide. In more recent studies, the
validity of receptor dimerization observed with TIRF analysis has
been assessed using SNAP-tagged forms of CD86 (known to be
monomeric) and comparing the intensity of its tracks with those
measured for SNAP-SNAP-CD86 (Calebiro et al., 2013) or SNAP-
CD28 (known to be dimeric) (Tabor et al., 2016).
SpIDA analysis on effects of ligands on muscarinic receptor or-
ganization has, to date, centred upon effects of antagonists. This
reﬂects the potential for agonists to promote internalization of the
receptor, and the approach requires analysis of receptors located at
the cell surface. In the future, use of inhibitors that interfere with
clathrin- or dynamin-mediated internalization may be useful. An
alternative, and potentially more clear-cut approach, may be to
employ genome-edited cells in which receptor internalization is
blocked: e.g. using b-arrestin 1/2 knockout HEK293 cells (Alvarez-
Curto et al., 2016).Please cite this article in press as: Marsango, S., et al., Muscarinic receptor
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rinic agonists as parts of wider studies on muscarinic oligomeri-
zation. For example, Herrick-Davis et al., (2013) made use of
Fluorescence Correlation Spectroscopy (FCS) with photon counting
histogram analysis to examine the oligomeric structure of a number
of class A GPCRs including the M1R and M2R. These studies
concluded that these receptors are exclusively dimeric and that
treatment with the agonist carbachol had no effect upon this
(Herrick-Davis et al., 2013).
Finally, in a wide range of studies sustained treatment with
antagonist ligands has resulted in upregulation of receptor levels
and enhanced cell surface delivery. The muscarinic antagonist
atropine has been found to increase expression and restore cell
surface delivery of many of the mutants that Liste and collaborators
generated and that showed the most impaired dimerization/olig-
omerization characteristics (Liste et al., 2015). Interestingly, long
term atropine treatment generally promoted enhanced organiza-
tion of such mutants, with the majority showing a more similar
organization to that of the wild-type receptor (Liste et al., 2015).
The role of so called molecular or pharmacological ‘chaperones’ has
been widely discussed in the context of receptor trafﬁcking and
clearly can promote oligomeric organization at the cell surface. This
is likely to be directly linked to early studies that centred on the role
of receptor dimerizationwithin the endoplasmic reticulum and the
idea of oligomeric contacts as a key quality control points in the
ontogeny of many GPCRs.oligomerization, Neuropharmacology (2017), https://doi.org/10.1016/
S. Marsango et al. / Neuropharmacology xxx (2017) 1e1083. Conclusions and future perspectives
In this review, we have summarized current knowledge
regarding the quaternary structure of the muscarinic acetylcholine
receptor family by considering both of early work, particularly
considering outcomes from ligand binding studies, and also results
derived from more recently adopted approaches. For at least the
M1R-M3R subtypes, where most work has been focussed, different
and sometimes contradictory quaternary arrangements, have been
described by various research groups. In this regard, it is important
to mention that a large scale comparative study has just been
published in which the quaternary structure of 60 class A
rhodopsin-like GPCRs was analysed by BRET- and single-molecule
microscopy-based assays (Felce et al., 2017). The conclusion was
that only a small proportion of class A GPCRs (about 23%) forms
authentic dimers while most of them, M3R included, are present as
monomers in HEK293 cells (Felce et al., 2017).
Moreover, the authors concluded that dimers were formed from
closely related phylogenetic clusters and that even closely related
receptors could be organized in different quaternary structures
(Felce et al., 2017). Finally, the authors hypothesised that dimer-
ization is an evolutionary process, one that increased the “ﬁtness
density” of those receptors, such as frizzled and glutamate, for
which dimerization is essential for their function preventing them
from diverging (Felce et al., 2017). This suggested why dimeriza-
tion, that does not confer functionality, is not a common future
among class A GPCRs (Felce et al., 2017).
Similarly, ligand binding to the receptors has been described as
able, or not, to alter the quaternary arrangement of muscarinic
receptors. However, despite this, the concept of class A GPCR olig-
omerization is onewhich hasmoved from the periphery of receptor
biology to the mainstream. A great deal of extra studies may be
required before a coherent picture of the quaternary structure and
physiological function of these receptors emerges and it is likely
that further studies on muscarinic receptors will be involved in
many aspects of this.
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